SciRhom GmbH has successfully raised EUR 63 million in Series A financing to advance its iRhom2-targeting therapies aimed at treating autoimmune diseases.
Target Information
SciRhom GmbH, based in Munich, Germany, is a biopharmaceutical company focusing on the development of innovative therapies targeting iRhom2 antibodies for autoimmune diseases. Founded with the mission to establish a new treatment paradigm, SciRhom aims to selectively influence TACE/ADAM17, a key regulator in various signaling pathways related to autoimmune conditions. The company has advanced its lead program, SR-878, designed to block multiple pro-inflammatory pathways while preserving essential functions, thus holding the potential for transformative effects across a range of autoimmune disorders.
Through strategic collaborations, including with co-founder Prof. Carl Blobel from the Hospital for Special Surgery, SciRhom has created a solid foundation of research and development. Notably, Prof. Blobel's research has significantly enriched the understanding of iRhom2's role in controlling inflammatory responses, contributing to the design of the SR-878 antibody that may lead to safer and more effective treatments.
Access Full Deal Insights
You’re viewing a public preview of this deal. To unlock full access to ca. 50,000 other deals in our database and join ca. 400 M&A professionals who are using it daily, sign up for Dealert.
Industry Overview
The biopharmaceutical industry in Germany is one of the leading sectors in Europe, characterized by rigorous research and innovation capabilities, robust academic partnerships, and a strong focus on developing
Similar Deals
Andera Partners, Kurma Partners, Hadean Ventures, MIG Capital, Wellington Partners, Bayern Kapital, High-Tech Gründerfonds, PhiFund Ventures
invested in
SciRhom GmbH
in 2024
in a Series A deal
Disclosed details
Transaction Size: $70M